Patents by Inventor Nicholas J. Papadopoulos

Nicholas J. Papadopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR
    Publication number: 20130157313
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: April 18, 2012
    Publication date: June 20, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Methods for Producing a Fusion Protein Capable of Binding VEGF
    Publication number: 20130149744
    Abstract: The present invention provides methods for producing a fusion protein capable of binding vascular endothelial cell growth factor (VEGF). The methods of the invention comprise growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule encoding a fusion protein that binds VEGF, and isolating the fusion protein from the suspension culture. The fusion protein may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 13, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • IGF-1 fusion polypeptides and therapeutic uses thereof
    Patent number: 8445434
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 21, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Methods for treating pruritus by administering an antibody that specifically binds human PAR2
    Patent number: 8425907
    Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: April 23, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
  • Cell culture compositions capable of producing a VEGF-binding fusion polypeptide
    Patent number: 8343737
    Abstract: The present invention provides cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: January 1, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 8338135
    Abstract: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 25, 2012
    Assignee: Regeneron Pharmaceuticals, inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 8337839
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: December 25, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • Fusion polypeptides capable of activating receptors
    Patent number: 8298532
    Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: October 30, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
  • Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody
    Publication number: 20120258098
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Application
    Filed: May 3, 2012
    Publication date: October 11, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20120195896
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Application
    Filed: March 9, 2012
    Publication date: August 2, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Method of treating rheumatoid arthritis with an anti-IL-6R antibody
    Patent number: 8192741
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: June 5, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR
    Publication number: 20120135010
    Abstract: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.
    Type: Application
    Filed: December 2, 2011
    Publication date: May 31, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
  • High affinity antibodies to human IL-6 receptor
    Patent number: 8183014
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: May 22, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • METHODS FOR TREATING PRURITUS BY ADMINISTERING AN ANTIBODY THAT SPECIFICALLY BINDS HUMAN PAR2
    Publication number: 20120093824
    Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.
    Type: Application
    Filed: December 14, 2011
    Publication date: April 19, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MACDONALD, Andrew J. MURPHY, Nicholas J. PAPADOPOULOS, Marc R. MORRA, Robert R. SALZLER, Michael L. LACROIX-FRALISH
  • IGF-1 fusion polypeptides and therapeutic uses thereof
    Patent number: 8158581
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 17, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide
    Publication number: 20120064621
    Abstract: The present invention provided cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
    Type: Application
    Filed: May 13, 2011
    Publication date: March 15, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR
    Publication number: 20120052072
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Application
    Filed: November 2, 2011
    Publication date: March 1, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • METHOD OF TREATING RHEUMATOID ARTHRITIS WITH AN ANTI-IL-6R ANTIBODY
    Publication number: 20120045440
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Application
    Filed: November 1, 2011
    Publication date: February 23, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • High-affinity human antibodies to human protease-activated receptor-2
    Patent number: 8101724
    Abstract: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: January 24, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 8092802
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: January 10, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos